Swedish medtech company Acarix has developed the CADScor System, a product that will help healthcare professionals in diagnosing individuals seeking treatment for symptoms related to coronary artery disease (CAD). The company recently received market approval for the device in the US, and CEO Per Persson visited the BioStock Studio at Medicon Village, Lund to tell us more about, among other things, the discussions with regulatory authorities, Acarix’s business strategy and the competitive landscape. 

Watch the interview with Acarix CEO Per Persson below:

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev